Results 91 to 100 of about 62,498 (301)

Analgesic Effects of Hydromorphone versus Buprenorphine in Buprenorphine-maintained Individuals. [PDF]

, 2019
BackgroundManaging acute pain in buprenorphine-maintained individuals in emergency or perioperative settings is a significant challenge. This study compared analgesic and abuse liability effects of adjunct hydromorphone and buprenorphine using ...
Tompkins, D Andrew, Strain, Eric C, Huhn, Andrew S, Edwards, Robert R, Smith, Michael T, Bigelow, George E   +5 more
core   +1 more source

An algorithm for seizure detection in rodents

Epilepsia Open, EarlyView.
Abstract Objective Epilepsy animal research often relies on long‐term intracranial electroencephalographic (iEEG) recordings. Here, we describe an artificial neural network (ANN) algorithm for automatic detection of seizures. Methods The algorithm was trained on iEEG recordings of three mouse models of chronic epilepsy: (1) the pilocarpine model of ...
Lyna Kamintsky, Gerben van Hameren, Itai Weissberg, Pooyan Moradi, Ofer Prager, Alaa Abu Ahmad, Lior Schori, Albert Becker, Yaniv Zigel, Alon Friedman   +9 more
wiley   +1 more source

Practices and Outcomes Associated With Sublingual Buprenorphine Use in a Critically Ill Population

Critical Care Explorations
IMPORTANCE:. Buprenorphine for opioid use disorder (OUD) is commonly used in the outpatient setting with increasing use in hospitalized patients. However, there is limited literature describing its use in critically ill populations. OBJECTIVES:.
Denis J. Vanini, PharmD, BCCCP, Jenna M. Corvelli, PharmD, BCCCP, Kaylee M. Maynard, PharmD, BCCCP, Stephen H. Rappaport, PharmD, BCCCP, Gina Grasso, PharmD, Raquel Jones, PharmD, BCPS, Nicole M. Acquisto, PharmD, FASHP, FCCM, FCCP, BCCCP, Rachel F. Schult, PharmD, DABAT   +7 more
doaj   +1 more source

Relationship between buprenorphine adherence and relapse, health care utilization and costs in privately and publicly insured patients with opioid use disorder

, 2018
Naoko A Ronquest,1 Tina M Willson,2 Leslie B Montejano,2 Vijay R Nadipelli,1 Bernd A Wollschlaeger3 1Global Health Economics and Outcomes Research, Indivior Inc., Richmond, VA, USA; 2Outcomes Research, Truven Health Analytics®, Part of the IBM Watson
Ronquest NA, Nadipelli VR, Wollschlaeger BA, Montejano LB, Willson TM   +4 more
core  

Fatalities within seven days after equine standing sedation: A prospective, multicentre study

Equine Veterinary Journal, EarlyView.
Abstract Background Information regarding mortality associated with standing procedures in horses is sparse. Objectives To report data from >12,000 standing sedations. Study Design Confidential, observational, prospective, multicentre, cohort study.
Miguel Gozalo‐Marcilla, José I. Redondo, Polly M. Taylor, Luis Domenech, Javier Doménech, Gordon Mark Johnston, Regula Bettschart‐Wolfensberger   +6 more
wiley   +1 more source

Advances in the delivery of buprenorphine for opioid dependence

, 2017
Richard N Rosenthal,1 Viral V Goradia2 1Department of Psychiatry, Addiction Institute at Mount Sinai, Icahn School of Medicine at Mount Sinai, New York, 2Department of Psychiatry, Upstate Medical University, Syracuse, NY, USA Abstract: Opioid use ...
Rosenthal RN, Goradia VV
core  

Addressing in‐hospital substance use: A bioethical evaluation of two possible approaches

Journal of Hospital Medicine, EarlyView.
Abstract Up to 40% of patients with substance use disorder report using non‐prescribed drugs when hospitalized. In‐hospital substance (IHSU) use is associated with poor outcomes and raises safety concerns for healthcare providers. Despite its prevalence, little guidance exists regarding best practices in responding to IHSU.
John C. Messinger, Taylor Baisey, Johanna Sluser, Benjamin A. Barsky, Marlene Martin, Leslie W. Suen   +5 more
wiley   +1 more source

Subst Use Misuse [PDF]

Background:Expanding access to medications to treat opioid use disorder (OUD), such as buprenorphine, is an evidence-based response to the mounting drug overdose crisis.

core  

Developing the Dopamine D3 Receptor (D3R) Antagonist, (R)‐VK4‐116, as a Non‐Opioid Medication for the Treatment of Opioid Use Disorder

Medicinal Research Reviews, EarlyView.
ABSTRACT Opioid use disorder (OUD) remains a major global health challenge, and currently approved treatments (methadone, buprenorphine, and naltrexone) are all opioid receptor‐targeting drugs with limitations in access, adherence, stigma, and use in polysubstance use disorders. Because the dopamine D3 receptor (D3R) is enriched in limbic brain regions
Chia‐Kuei Wu, Yu‐Chih Lin, Junfeng Huang, Bangwei Ding, Pramod Terse, Rahul Nandre, Haksong Jin, Molly Congdon, Kun Shen, Philip Sanderson, Gregory Tawa, Stephanie Mounaud, Marta De Santis, Donald Lo, Elizabeth A. Ottinger, Amy Hauck Newman   +15 more
wiley   +1 more source

Effects of buprenorphine on pain perception in healthy adults: a meta-narrative systematic review

PAIN Reports
. The availability of knowledge about the effects of buprenorphine on pain perception in healthy adults could help investigators select experimental tests with evidence of responsiveness to buprenorphine in nondiseased states.
W. Michael Hooten, Danielle Zheng, Nicholas C. Canzanello, Rajat N. Moman, Larry Prokop, Nathan D. Eberhart, Barlas Benkli, Salman Hirani   +7 more
doaj   +1 more source